Sareum (LON:SAR) Stock Price Crosses Below 50 Day Moving Average – Here’s What Happened

Sareum Holdings plc (LON:SAR) shares crossed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 16.10 ($0.22) and traded as low as GBX 14.35 ($0.19). Sareum shares last traded at GBX 15.10 ($0.20), with a volume of 423,769 shares trading hands.

Sareum Stock Performance

The stock’s 50-day moving average is GBX 16.10 and its 200 day moving average is GBX 18.82. The firm has a market cap of £18.86 million, a P/E ratio of -3.58 and a beta of -1.08.

Sareum (LON:SAR) last released its quarterly earnings data on Tuesday, March 25th. The company reported GBX (0.90) (($0.01)) EPS for the quarter. On average, research analysts anticipate that Sareum Holdings plc will post -3.8 EPS for the current year.

Insiders Place Their Bets

In other news, insider Stephen Parker bought 84,033 shares of the stock in a transaction on Wednesday, March 26th. The stock was purchased at an average price of GBX 12 ($0.16) per share, for a total transaction of £10,083.96 ($13,537.33). Corporate insiders own 5.02% of the company’s stock.

About Sareum

Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.